This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).
Official Title
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis
Conditions
- Allergy
Study Type
Interventional
Study Design
Treatment, Randomised, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study.
Further Details
- Recording of rhinoconjunctivitis symptoms
[Time Frame: After the grass pollen seasons 2007, 2008 and 2009]
[Designated as safety issue: No] - Recording of use of rescue medication
[Time Frame: After the grass pollen seasons 2007, 2008 and 2009]
[Designated as safety issue: No]
- Quality of life
[Time Frame: After the grass pollen seasons 2007, 2008 and 2009]
[Designated as safety issue: No]
Study Start
October 2004
Eligibility & Criteria
Eligibility Criteria:
- A history of grass pollen induced rhinoconjunctivitis
- Positive skin prick test to grass
- Positive specific IgE to grass
Total Enrolment
634
Contact Details
Please refer to this study by its ClinicalTrials.gov identifier: NCT00227279
Study Director:
Mette Ribel, MSc
ALK-Abello A/S
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.